Drug Profile
Research programme: microenvironment-activated therapeutics - XTuit Pharmaceuticals
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator XTuit Pharmaceuticals
- Class Antifibrotics; Antineoplastics
- Mechanism of Action Extracellular matrix protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Liver cirrhosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in USA
- 28 Jul 2019 No recent reports of development identified for research development in Liver-Cirrhosis in USA
- 28 Jul 2019 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA